

Surgical treatment of the neck in patients with salivary gland carcinoma

Westergaard-Nielsen, Marie; Godballe, Christian; Grau Eriksen, Jesper; Larsen, Stine Rosenkilde; Kiss, Katalin; Agander, Tina; Parm Ulhøi, Benedicte; Wittenborg Charabi, Birgitte; Ehlers Klug, Tejs; Jacobsen, Henrik; Johansen, Jørgen; Kristensen, Claus Andrup; Andersen, Elo; Andersen, Maria; Bjørndal, Kristine

Published in:
Head and Neck

DOI (link to publication from Publisher):
[10.1002/hed.26667](https://doi.org/10.1002/hed.26667)

Publication date:
2021

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Westergaard-Nielsen, M., Godballe, C., Grau Eriksen, J., Larsen, S. R., Kiss, K., Agander, T., Parm Ulhøi, B., Wittenborg Charabi, B., Ehlers Klug, T., Jacobsen, H., Johansen, J., Kristensen, C. A., Andersen, E., Andersen, M., & Bjørndal, K. (2021). Surgical treatment of the neck in patients with salivary gland carcinoma. *Head and Neck*, 43(6), 1898-1911. <https://doi.org/10.1002/hed.26667>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

Take down policy

If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from vbn.aau.dk on: December 05, 2025

Surgical treatment of the neck in patients with salivary gland carcinoma

Marie Westergaard-Nielsen MD^a, Christian Godballe professor^a, Jesper Grau Eriksen professor^b, Stine Rosenkilde Larsen MD^c, Katalin Kiss MD^d, Tina Agander PhD^d, Benedicte Parm Ulhøi MD^e, Birgitte Charabi MD^f, Tejs Ehlers Klug DMSc^g, Henrik Jacobsen MD^h, Jørgen Johansen PhDⁱ, Claus Andrup Kristensen PhD^j, Elo Andersen MD^k, Maria Andersen MD^l, Kristine Bjørndal PhD^a

^a Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark

^b Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

^c Department of Pathology, Odense University Hospital, Odense, Denmark

^d Department of Pathology, Rigshospitalet, Copenhagen, Denmark

^e Department of Pathology, Aarhus University Hospital, Aarhus, Denmark

^f Department of Otorhinolaryngology, Head and Neck Surgery, Rigshospitalet, Copenhagen, Denmark

^g Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital, Aarhus, Denmark

^h Department of Otorhinolaryngology, Head and Neck Surgery, Aalborg University Hospital, Aalborg, Denmark

ⁱ Department of Oncology, Odense University Hospital, Odense, Denmark

^j Department of Oncology, Rigshospitalet, Copenhagen, Denmark

^k Department of Oncology, Herlev, Herlev, Denmark

^l Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

Corresponding author

Marie Westergaard-Nielsen M.D., ORCID nr 0000-0002-9348-7078

Department of ORL – Head and Neck Surgery and Audiology, Odense University Hospital

J.B. Winsloews Vej 4, 5000 Odense C, Denmark

Tlf: +45 30 29 83 06, email: marie.westergaard.nielsen@rsyd.dk

Running title: Surgical treatment of the neck

Key words: Salivary gland carcinoma, neck dissection, cervical lymph nodes, regional metastases, surgery

Grant support: The study was conducted as part of PhD funded by grants from University of Southern Denmark, Region of Southern Denmark, Danish Cancer Research Fund, and Danish Cancer Society.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/hed.26667](https://doi.org/10.1002/hed.26667)

This article is protected by copyright. All rights reserved.

Abstract

Background Elective neck dissection (END) in patients with salivary gland carcinoma is controversial and there are no universally accepted guidelines.

Methods Patients were identified from the Danish Head and Neck Cancer Group. Between 2006 and 2015, 259 patients with primary salivary gland carcinoma were treated with END. Variables potentially associated with regional metastases were analysed using logistic regression. Neck recurrence-free survival was calculated using the Kaplan–Meier method.

Results Occult metastases were found in 36 of the patients treated with END (14%) and were particularly frequent among patients with T3/T4 tumours and high-grade histology tumours. In multivariate analyses, high-grade histology and vascular invasion were associated with occult metastases.

Conclusion We recommend END of levels II and III for patients with high-grade or unknown histological grade tumours, and for T3/T4 tumours. Levels I, II, and III should be included in END in patients with submandibular, sublingual, or minor salivary gland carcinomas.

Introduction

Cervical lymph node metastasis is a negative prognostic factor in patients with salivary gland carcinoma (1-6), and therapeutic neck dissection (TND) is recommended in patients with clinically involved cervical lymph nodes (7-12). However, there are no universally accepted guidelines on the surgical treatment of patients with clinically negative neck. Salivary gland carcinoma is a heterogeneous disease, and treatment strategies depend on the histological subtypes and anatomical locations of tumours, as well as the stage of the disease.

Current practice in Denmark is TND in patients with clinically positive cervical lymph nodes, and elective neck dissection (END) is recommended in patients with T3/T4 tumours, high-grade histology tumours, or in cases of facial nerve palsy (13). This approach is supported by studies that recommend END in patients with high-grade histology tumours or advanced tumour classifications (8, 11, 12, 14-21). Other studies have recommended END in all patients with salivary gland carcinomas (22-26), because preoperative evaluations of histological tumour subtypes and grades are unreliable and there is a risk of regional metastases even for low-grade histology tumours. Occult regional metastases have been reported in 12%–45% of patients with salivary gland carcinomas (8, 16, 19, 23, 24, 26-30), with the highest incidence among patients with high-grade histological subtypes (4, 8, 16, 27, 29, 31). Preoperative characteristics such as large tumours, older age, facial palsy, and extra-parotid extension of the primary tumour have also been associated with regional metastases (1, 5, 11, 32, 33).

In this study, we evaluate results from all Danish patients diagnosed with salivary gland carcinomas over a period of 10 years. We identify clinical and pathological factors associated with regional metastases and occult metastases, and we recommend an approach to surgical treatment of the neck in patients with salivary gland carcinoma but no clinically suspected regional metastases.

Material and Methods

This was a retrospective study with inclusion of all patients diagnosed with previously untreated primary salivary gland carcinoma in Denmark between 1 January 2006 and 31 December 2015.

Patients were identified from the national Danish Head and Neck Cancer Group (DAHANCA) database. Completeness of the database was verified by cross referencing with two additional national databases: The Danish Cancer Register, and The Danish Pathology Register. We included patients treated with intended curative surgery of the primary site, with or without neck dissection. Information on diagnostic procedures, surgical treatments and follow-up data were obtained from medical records and pathology reports. All available pathological specimens of primary tumours were histologically revised by one of four experienced salivary gland pathologists (SRL, KK, BPU and TA). Histological subtypes were classified according to the World Health Organization (WHO) 2017 classification system for salivary gland carcinoma (34).

A total of 730 patients were diagnosed with salivary gland carcinoma during the inclusion period. Patients with distant metastases at the time of diagnosis ($n = 42$) and patients given primary radiotherapy, palliative treatment, or no treatment ($n = 24$) were excluded. Of the 664 patients treated with surgery, 81 had clinically suspicious lymph nodes (cN+) and 583 had clinically negative lymph nodes (cN0). Patients with cN+ were treated with TND. For patients with cN0, the primary tumour site was excised followed by either no neck dissection (noND) ($n = 324$) or END ($n = 259$). A flow chart showing inclusion is provided in Figure 1.

TND was defined as neck dissection in patients with clinically (including radiographically) suspected cervical lymph node metastases. END was defined as neck dissection in patients with cN0. Occult metastases were defined as histologically confirmed metastases (pN+) in clinically negative lymph nodes (i.e., cN0pN+). The proportion of occult metastases was defined as the ratio between patients with cN0pN+ and patients treated with END. Regional metastases were defined as metastases in cervical lymph nodes. Vascular invasion was equivalent to lymphovascular invasion.

Clinical N-classifications were determined by clinical examination and diagnostic imaging using ultrasonography ($n = 389$, 57%), computed tomography (CT) ($n = 270$, 40%), magnetic resonance imaging (MRI) ($n = 342$, 51%) and/or positron emission/computed tomography (PET/CT) ($n = 193$, 29%). If lymph node metastases were suspected from one of the diagnostic modalities, the clinical N-classification was defined as positive (cN+). Tumours were classified according to the Union for International Cancer Control (UICC) TNM 8th edition (35).

Preoperative decision on END was made by the patient and surgeon or a multidisciplinary team including a surgeon, oncologist, and radiologist. In accordance with the Danish treatment guidelines for salivary gland carcinoma, patients with T1/T2 tumours were offered END if fine needle aspiration from the primary tumour revealed malignant cells with high-grade or histologically undefined subtype, or in case of facial nerve palsy. Patients with T3/T4 tumours were offered END irrespective of histological grade or subtype (13). The criteria for postoperative radiotherapy were positive surgical margins, high-grade histology, T3/T4 tumour, cervical lymph node metastases, or perineural invasion.

Histological subtypes were categorised as high- or low-grade malignancies in accordance with Danish guidelines (13), as shown in Supplementary Table A.

Statistics

Variables potentially associated with histologically proven metastases (pN+) were analysed using univariate and multivariate logistic regression. These associations were evaluated by calculating odds ratios (OR). The test were two-sided, and a p -value < 0.05 was considered significant.

Estimates of neck recurrence-free survival (neck-RFS) were calculated using the Kaplan–Meier method.

Follow-up time was calculated from the date of primary surgical treatment to the date of death or the end of data-collection (January 2018). Data were stored in a RedCap database provided by the Open Patient data Explorative Network (OPEN). Statistical analysis was performed using Stata ver. 16 (StataCorp LLC, College Station, Texas, USA).

Results

The study cohort consisted of 304 (46%) men and 360 (54%) women with a median age of 62 years (range, 6–94 years). Histological re-evaluation was performed in 639 (96.2%) cases.

A total of 259 patients were treated with surgery for the primary tumour and END. Occult metastases were histologically confirmed in 36 of the 259 patients (14%). The characteristics of patients treated with TND, END or noND are compared in Table 1.

Fifty of the 81 patients (62%) with cN+ (treated with TND) had histologically confirmed lymph node metastases (pN+). A total of 86 of the 340 patients (25%) treated with TND or END had pN+.

The median follow-up time for the entire cohort was 4.8 years (range, 0.1–12.5 years). For patients who remained alive at the end of data collection, the median follow-up time was 5.5 years (range, 2–12.5 years). For patients treated with END, the median follow-up time was 4.7 years (range, 0.1–12.3 years).

In univariate analyses of patients with pN+ versus those with no histological evidence of regional lymph node metastasis (pN0) (340 patients), all variables (i.e., male sex, age >60 years, T3/T4-classification, tumour size ≥ 4 cm, major glands, facial nerve impairment, high-grade histological subtype, involved surgical margins, perineural invasion, and perivascular invasion) were significantly associated with regional metastases. In the multivariate analyses, only high-grade histological subtypes, male sex, and vascular invasion were significantly associated with regional metastases. Information on perineural and vascular invasion were missing for 108 (32%) and 203 (60%) patients, respectively. Data from patients with pN+ and pN0, as well as the results from the regression analyses are compared in Table 2.

Occult metastases

Overall, the proportion of patients with histologically verified occult metastases among those treated with END was 14% (36/259). Among patients with high-grade histology tumours, the proportion of occult

metastases was 27% (20/74) and it was 9% (16/185) among patients with low-grade histology tumours. Similarly, the proportion of occult metastases was 22% (14/63) among patients with T3/T4 tumours and among those with T1/T2 tumours it was 11% (22/196). In total, 18% (21/115) of males and 10% (15/144) of females, treated with END, had occult metastases. The proportion of patients with occult metastases varied among those with a primary tumour in the parotid gland (15%), the submandibular gland (15%), the sublingual gland (25%), and the minor glands (5%). Univariate analyses of the END group showed that T3/T4 tumours, high-grade histological subtype, facial nerve impairment, as well as perineural and vascular invasion were all associated with occult metastases. In the multivariate analyses, only high-grade histological subtype and vascular invasion were significantly associated with occult metastases. The characteristics of patients with occult metastases and results from the regression analyses are summarised in Table 3.

Treatment at neck node levels

Regional metastases were observed in all neck node levels (I–V) in patients treated with either END or TND. Levels II and III were most frequently dissected. The numbers of patients treated with END and TND at each neck node level as well as the proportions of patients with metastases are summarised in Supplementary Table B. Figure 2 shows the distribution of occult metastases at different neck node levels. Occult metastases in level I were diagnosed in four patients with either submandibular gland carcinoma ($n = 3$, 75%) or sublingual gland carcinoma ($n = 1$, 25%). One patient with submandibular gland carcinoma had occult metastases in level III, but no metastases in levels I or II (after END of levels I–III). All other patients with occult metastases in levels III, IV, and V also had metastases in level II. Three patients had occult metastases in level IV, and all three had high-grade histology tumours with advanced T-classification (a T3 lymphoepithelial carcinoma, a T3 salivary duct carcinoma, and a T4a poorly differentiated carcinoma). Two patients had occult metastases in level V and also in levels III and IV; thus, there were no skip metastases in level V.

Recurrences

During follow-up, a total of 33 patients (5%) showed recurrence in cervical lymph nodes (i.e., regional recurrence). At the time of diagnosis, 16 of these patients (48%) had pN+, nine patients (27%) had pN0 and eight patients (24%) had noND. In total, 14 patients (42%) had been treated with TND, and 10 of these patients also received postoperative radiotherapy for the cervical lymph nodes (i.e., regional radiotherapy). Eleven patients (33%) had been treated with END, and one of them also had postoperative regional radiotherapy. A total of 21 patients (64%) with regional recurrence had not been treated with postoperative regional radiation. In five patients treated with neck dissection and postoperative radiotherapy (>50 Gy), recurrence was observed within the irradiated field. In seven patients treated with neck dissection and postoperative radiotherapy, recurrence occurred in cervical lymph nodes outside the area treated by surgery and radiotherapy.

Among the eight patients treated with noND, two had been given locoregional radiotherapy. Both patients had parotid gland carcinoma and high-grade histology tumours. Both recurrences occurred outside the irradiated field. Table 4 summarises information on patients with noND and regional recurrence.

Figure 3 shows Kaplan–Meier curves comparing neck-RFS in patients with pN+, pN0 and noND. The 5- and 10-year neck-RFS were 77% and 57% for patients with pN+, 98% and 94% for patients with pN0, and 98% and 96% for patients treated with noND, respectively. There were no differences in recurrence rates for patients with noND when stratified by radiotherapy (i.e., elective versus no neck radiotherapy) or histological tumour grade (i.e., high-grade versus low-grade).

Discussion

This is the largest national study on surgical treatment of the neck in patients with salivary gland carcinoma involving a complete cohort of unselected patients with re-evaluated histological diagnoses.

Our results support the current consensus on treating patients with cN+ with TND (12, 14, 20, 21, 36).

Achieving a consensus on guidelines for END in patients with cN0 is more difficult. Studies have found occult metastases in 6–45% of patients with salivary gland carcinomas (4, 8, 12, 14, 15, 17, 20, 21, 23, 26, 27, 30, 37-47). We found occult metastases in 14% of patients who had been treated with END. This proportion may be an overestimate because patients were selected for END based on known risk factors. If the proportion of patients with occult metastases were calculated using all cN0 patients, instead of only cN0 patients treated with END, there would be a risk of underestimating the true proportion of occult metastases due to unrecognised metastases in the NoND group.

Studies reporting the highest proportions of occult metastases selected those patients with advanced T-classifications (T3/T4) and high-grade histology tumours for END (8, 14, 17, 20, 30, 44). Variation in the staging procedures, preoperative diagnostic imaging methods, and histological grading definitions may have influenced the assessment of cervical lymph nodes in these studies and hence the proportions of occult metastases reported. In our study, only 12% of patients were cN+, presumably because we included the entire national cohort without selecting for aggressive tumours or particular anatomical subsites.

Our results showed that regional recurrence was significantly more frequent among patients with pN+ than among those with pN0 and those who had noND. However, the neck-RFS of patients with pN0 was similar to that of patients who had noND. Two patients (2/324, 0.6%) with noND had regional recurrence within the first year of follow-up. This relatively short time to recurrence may imply the presence of undiagnosed occult lymph node metastases. Considering the indications for END, all but one of the patients with noND and regional recurrence (Table 4) should have undergone END, but for various reasons they did not.

The proportions of patients with pN0 and noND who had elective radiotherapy of the neck were nearly identical. Regional recurrence occurred in 33 patients, and 12 (36%) of these patients had received radiotherapy with >50 Gy. In five of these 12 patients (42%), recurrence was observed within the irradiated field. Other studies have reported that elective neck radiotherapy decreased the risk of regional recurrence (1, 48) and that radiotherapy may be a better treatment option than neck dissection for patients receiving

adjuvant radiotherapy at primary tumour site (19). The proportion of patients with false-positive regional metastases after clinical evaluation was relatively high (31/81 patients, 38% of those with cN+). During follow-up, two of these patients were diagnosed with regional recurrence. Both patients had received postoperative radiotherapy at the primary tumour site but no elective neck radiotherapy. In both cases, recurrence occurred within the first year after the primary diagnosis and in neck node levels that had been included in the TND. This highlights a risk of false negative pathological evaluation and suggests that these patients would have benefitted from postoperative elective neck radiotherapy.

In this study, occult metastases occurred most frequently in patients with adenoid cystic carcinoma, followed by patients with salivary duct carcinoma. Several studies have reported a high frequency of occult metastases among patients with adenoid cystic carcinoma (37, 49, 50), whereas other studies have reported the highest rates of occult metastases among patients with adenocarcinoma, mucoepidermoid carcinoma, undifferentiated carcinoma, squamous cell carcinoma and salivary duct carcinoma (8, 17, 26, 27). Some studies recommend an individual assessment for END in patients with cN0 (38-40, 51), whereas other studies recommend END for all patients with high-grade histology or T3/T4 tumours (8, 14, 15, 17, 20, 21, 45). Several studies recommend END for all patients with salivary gland carcinomas (22, 23, 25), because preoperative diagnoses are inaccurate and occult metastases may occur in low-grade as well as high-grade histological subtypes. A previous recommendation that neck dissection was indicated for patients with squamous cell carcinoma if the risk of metastases was greater than 15-20% (52-54) has recently been challenged (55). The proportion of occult metastases observed in our study (14%), suggest that END should not be recommended for all patients with salivary gland carcinoma.

The decision for END as part of the primary surgical procedure is based on preoperatively known factors. Perineural invasion, vascular invasion, and surgical margins are preoperatively unknown and the same usually applies for histological grade or subtype as well. Preoperative diagnoses and surgical assessments are often based on fine needle biopsies from the primary tumour, but cytological classification of subtypes

and histological grade is inaccurate (56, 57). Consequently, reliable subtype and histological grade data may be unavailable prior to surgery, and we suggest that these cases should be treated as high-grade histology tumours. Here, high-grade histology tumours were significantly associated with metastases in analyses of all patients and analyses of patients with occult metastases. Therefore, we recommend END for patients with high-grade histological subtypes, irrespective of tumour classification. Importantly, if END is not performed during the primary surgical procedure and the histological examination reveals high-grade histology in tumours that were preoperatively assessed as low-grade, END may be performed as an additional surgical procedure. Elective neck radiotherapy may be used as an alternative to supplementary END for patients receiving postoperative radiotherapy due to characteristics of the primary tumour.

Tumour class was not a significant risk factor for occult metastases in the multivariate analyses, but the proportion of occult metastases in patients with T4/T4 was 22%, compared to 11% in patients with T1/T2 tumours. Therefore, we recommend END for patients with T3/T4 tumours. Several other studies have reported a significant association between regional metastases and advanced tumour size or classification (T3/T4 tumours) (8, 17, 20, 21, 58).

The likelihood of occult metastases was also influenced by the location of the primary tumour. Only 5% of patients with primary tumours in the minor salivary glands had occult metastases. Lee *et al.* (59) reported a high proportion of occult metastases (25%) among patients with carcinomas in the minor glands. Our data are not consistent with these results, probably because a relatively large proportion of patients with minor gland carcinomas were treated with END. The highest proportion of occult metastases by subsite in our study (25%) was observed in patients with sublingual gland carcinomas. The large proportion of patients with sublingual gland carcinomas who had occult metastases justifies END in these patients, and this is consistent with other studies (41, 60). Regional metastases have been reported in 27–40% of patients with submandibular carcinomas (61–63), and occult metastases have been reported in up to 22% of patients with submandibular carcinomas who were treated with END (2). Considering that submandibular gland

carcinomas frequently are high-grade histological subtypes (61), END should be relevant for most of these patients.

Extent of elective neck dissection

Few studies have assessed recommendations for the extent of END. Occult metastases are most frequently reported in neck node levels II and III (8, 14, 20, 21, 44, 45). Our results are consistent with those studies, and we found most occult metastases in neck node levels II and III, regardless of the primary site. Importantly, these levels were also most frequently dissected. The proportions of occult metastases per dissected level were high in neck node levels IV and V, but these levels were only dissected in 19 and 18 selected patients, respectively. Lim *et al.* (64) studied the elective dissection of neck node level V in patients with parotid carcinomas and concluded that this was not obligate in patients with cN0. Stodulski *et al.* (45) reported that occult metastases occurred in neck node level V at a frequency of 30% in their group of patients and recommended including level Va in END of patients with T3/T4 tumours, but other studies have reported that occult metastases occur in level IV at a frequency of 0–11% and in level V at a frequency of 0–7% (8, 12, 14, 15, 20, 21, 27, 39). Consequently, we do not recommend including level V in the standard END procedure. In our study, occult metastases in level I were nearly almost found in patients with submandibular gland carcinoma, and nearly half of the patients with pN+ submandibular gland carcinomas had metastases in neck node level I (8/17, 47%). This supports the recommendation to include lymph nodes from levels I, II, and III in the primary surgical treatment of submandibular gland carcinomas, as suggested by other studies (38, 61).

Based on recommendations from other studies and our results, we suggest that END should include levels II and III in patients with parotid gland carcinomas, and levels I, II, and III in patients with submandibular gland carcinomas, sublingual gland carcinomas, or carcinomas in the minor oral salivary glands. If occult metastases are histologically diagnosed, levels IV and V should also be dissected. Alternatively, if these patients are receiving postoperative radiotherapy, the target field may be adjusted to include neck node levels IV and V, thereby avoiding a second surgical procedure. Intraoperative diagnosis with frozen section

of lymph nodes may enable an extension of the primary surgical procedure with END if regional metastases are identified peroperatively. Recent review studies by Vander Poorten *et al.* (65) and Lombardi *et al.* (66) suggested frozen section of lymph nodes from level II, and to proceed with the neck dissection if occult metastases are identified. In this study, only one patient had skip occult metastases to level III with no metastases in levels I and II. All other patients with metastases in levels III, IV and V also had metastases in level II. This observation supports using elective lymph node excision or selective dissection of level II for peroperative frozen sections. In this study, there was limited scope for evaluating the use of frozen section but this may be possible in future studies.

Limitations

This study had some limitations. Data collection was restricted by the retrospective study design. Different diagnostic imaging methods were used, and the quality of these methods may have influenced the clinical assessment of cervical lymph nodes and the evaluation of occult metastases. Pooling multiple subtypes in the analyses may have influenced outcomes, and the heterogeneity of salivary gland carcinomas restricts the generalisability of recommendations. Patients were selected for neck dissection, and the extent of the surgical procedure varied. Neck node levels II and III were most frequently dissected and occult metastases may have been present in other levels that were not dissected and histologically evaluated. In addition, these non-dissected levels may not reveal occult metastases if patients received postoperative neck radiation. A prospective study with uniform diagnostic and treatment methods would overcome these limitations.

Conclusion

In patients with salivary gland carcinoma and cN0, T-classification and histological grade are often used as indications for END. For patients with T3/T4 tumours, high-grade histological tumours, or unknown grade prior to surgery, we recommend END of neck node levels II and III. Levels I–III should be included in patients

with carcinoma in the submandibular gland, sublingual gland, or minor oral salivary glands. Selected patients with cN0 and low-grade histology T1/T2 tumours may be treated by observation and follow-up, but individual assessments are always necessary and should take patient preference and the location, size and clinical stage of the primary tumour into account.

Acknowledgements

The study was supported by the Danish Head and Neck Cancer Group (DAHANCA) and by OPEN, Odense Patient data Explorative Network, Odense University Hospital, Denmark. Special acknowledgement to Simon Andreasen (†) and Annelise Kroghdahl for their assistance with histological specimens.

The study was supported by PhD research grants from the University of Southern Denmark, the Region of Southern Denmark, the Danish Cancer Research Fund, and the Danish Cancer Society.

None of the authors have any conflicts of interest. This work was approved by all the affiliated institutions.


References

1. Frankenthaler RA, Luna MA, Lee SS, Ang KK, Byers RM, Guillaumondegui OM, et al. Prognostic variables in parotid gland cancer. *Archives of otolaryngology--head & neck surgery*. 1991;117(11):1251-6.
2. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Loftus-Coll BM, Keus RB, et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. *Cancer*. 1999;85(10):2255-64.
3. Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. *Head & neck*. 2004;26(8):681-92; discussion 92-3.
4. Lim YC, Lee SY, Kim K, Lee JS, Koo BS, Shin HA, et al. Conservative parotidectomy for the treatment of parotid cancers. *Oral Oncol*. 2005;41(10):1021-7.
5. Qian K, Sun W, Guo K, Zheng X, Sun T, Chen L, et al. The number and ratio of positive lymph nodes are independent prognostic factors for patients with major salivary gland cancer: Results from the surveillance, epidemiology, and End Results dataset. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. 2018.
6. Godballe C, Schultz JH, Krogdahl A, Moller-Grontved A, Johansen J. Parotid carcinoma: impact of clinical factors on prognosis in a histologically revised series. *Laryngoscope*. 2003;113(8):1411-7.
7. Vander Poorten V, Hunt J, Bradley PJ, Haigentz M, Jr., Rinaldo A, Mendenhall WM, et al. Recent trends in the management of minor salivary gland carcinoma. *Head & neck*. 2014;36(3):444-55.
8. Armstrong JG, Harrison LB, Thaler HT, Friedlander-Klar H, Fass DE, Zelefsky MJ, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. *Cancer*. 1992;69(3):615-9.
9. Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. *Journal of Oral and Maxillofacial Surgery*. 2005;63(7):917-28.
10. Gold DR, Annino DJ, Jr. Management of the neck in salivary gland carcinoma. *Otolaryngol Clin North Am*. 2005;38(1):99-105, ix.
11. Medina J, Zbaren P, Bradley PJ. Management of Regional Metastases of Malignant Salivary Gland Neoplasms. *Adv Otorhinolaryngol*. 2016;78:132-40.
12. Yoo SH, Roh JL, Kim SO, Cho KJ, Choi SH, Nam SY, et al. Patterns and treatment of neck metastases in patients with salivary gland cancers. *J Surg Oncol*. 2015;111(8):1000-6.
13. DAHANCA. Nationale retningslinier for udredning og behandling af spytkirtelkræft i Danmark. 2018, Ver 1.1.
14. Ali S, Palmer FL, DiLorenzo M, Shah JP, Patel SG, Ganly I. Treatment of the neck in carcinoma of the parotid gland. *Ann Surg Oncol*. 2014;21(9):3042-8.
15. Klusmann JP, Ponert T, Mueller RP, Dienes HP, Guntinas-Lichius O. Patterns of lymph node spread and its influence on outcome in resectable parotid cancer. *European Journal of Surgical Oncology*. 2008;34(8):932-7.
16. Rodriguez-Cuevas S, Labastida S, Baena L, Gallegos F. Risk of nodal metastases from malignant salivary gland tumors related to tumor size and grade of malignancy. *European Archives of Oto-Rhino-Laryngology*. 1995;252(3):139-42.
17. De Brito Santos IR, Kowalski LP, Cavalcante de Araujo V, Flavia Logullo A, Magrin J. Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas. *Archives of Otolaryngology - Head and Neck Surgery*. 2001;127(1):56-60.
18. Ettl T, Gosau M, Brockhoff G, Schwarz-Furlan S, Agaimy A, Reichert TE, et al. Predictors of cervical lymph node metastasis in salivary gland cancer. *Head and Neck*. 2014;36(4):517-23.


19. Herman MP, Werning JW, Morris CG, Kirwan JM, Amdur RJ, Mendenhall WM. Elective neck management for high-grade salivary gland carcinoma. *American journal of otolaryngology*. 2013;34(3):205-8.
20. Shinomiya H, Otsuki N, Yamashita D, Nibu K. Patterns of lymph node metastasis of parotid cancer. *Auris Nasus Larynx*. 2016;43(4):446-50.
21. Jinnin T, Kawata R, Higashino M, Nishikawa S, Terada T, Haginomori SI. Patterns of lymph node metastasis and the management of neck dissection for parotid carcinomas: a single-institute experience. *International Journal of Clinical Oncology*. 2019.
22. Kawata R, Koutetsu L, Yoshimura K, Nishikawa S, Takenaka H. Indication for elective neck dissection for N0 carcinoma of the parotid gland: A single institution's 20-year experience. *Acta Oto-Laryngologica*. 2010;130(2):286-92.
23. Zbaren P, Schupbach J, Nuyens M, Stauffer E. Elective neck dissection versus observation in primary parotid carcinoma. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2005;132(3):387-91.
24. Stenner M, Molls C, Luers JC, Beutner D, Klusmann JP, Huettenbrink KB. Occurrence of lymph node metastasis in early-stage parotid gland cancer. *European Archives of Oto-Rhino-Laryngology*. 2011;1-6.
25. Nobis CP, Rohleder NH, Wolff KD, Wagenpfeil S, Scherer EQ, Kesting MR. Head and neck salivary gland carcinomas - Elective neck dissection, yes or no? *Journal of Oral and Maxillofacial Surgery*. 2014;72(1):205-10.
26. Stennert E, Kisner D, Jungehuelsing M, Guntinas-Lichius O, Schroder U, Eckel HE, et al. High incidence of lymph node metastasis in major salivary gland cancer. *Archives of Otolaryngology - Head and Neck Surgery*. 2003;129(7):720-3.
27. Lau VH, Aouad R, Farwell DG, Donald PJ, Chen AM. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: Refining the role of elective neck irradiation. *Head and Neck*. 2014;36(10):1435-9.
28. Lloyd S, Yu JB, Ross DA, Wilson LD, Decker RH. A Prognostic Index for Predicting Lymph Node Metastasis in Minor Salivary Gland Cancer. *International Journal of Radiation Oncology Biology Physics*. 2010;76(1):169-75.
29. Villepelet A, Lefevre M, Verillaud B, Janot F, Garrel R, Vergez S, et al. Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Reseau d'Expertise Francais des Cancers ORL Rares. *Head & neck*. 2019;41(3):584-91.
30. Westergaard-Nielsen M, Rosenberg T, Gerke O, Dyrvig AK, Godballe C, Bjørndal K. Elective neck dissection in patients with salivary gland carcinoma: A systematic review and meta-analysis. *Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology*. 2020.
31. Zhan KY, Lentsch EJ. Oncocytic carcinoma of the major salivary glands: A population-based study of 278 cases. *Head & neck*. 2016;38 Suppl 1:E1981-6.
32. Jayaprakash V, Merzianu M, Warren GW, Arshad H, Hicks WL, Jr., Rigual NR, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. *Head & neck*. 2014;36(5):694-701.
33. Xiao CC, Zhan KY, White-Gilbertson SJ, Day TA. Predictors of Nodal Metastasis in Parotid Malignancies: A National Cancer Data Base Study of 22,653 Patients. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2016;154(1):121-30.
34. El-Naggar AK CJ, Grandis JR, Takata T, Slootweg PJ. WHO Classification of Head and Neck Tumours. Lyon: International Agency for Research on Cancer (IARC) 2017.
35. Brierley J GM, Wittekind C TNM classification of malignant tumours. Union for International Cancer Control: Wiley, Chichester; 2017.

36. Chisholm EJ, Elmiyeh B, Dwivedi RC, Fisher C, Thway K, Kerawala C, et al. Anatomic distribution of cervical lymph node spread in parotid carcinoma. *Head and Neck*. 2011;33(4):513-5.
37. Amit M, Binenbaum Y, Sharma K, Ramer N, Ramer I, Agbetoba A, et al. Incidence of cervical lymph node metastasis and its association with outcomes in patients with adenoid cystic carcinoma. An international collaborative study. *Head and Neck*. 2015;37(7):1032-7.
38. Aro K, Tarkkanen J, Saat R, Saarilahti K, Makitie A, Atula T. Submandibular gland cancer: Specific features and treatment considerations. *Head and Neck*. 2018;40(1):154-62.
39. Chang JW, Hong HJ, Ban MJ, Shin YS, Kim WS, Koh YW, et al. Prognostic Factors and Treatment Outcomes of Parotid Gland Cancer: A 10-Year Single-Center Experience. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2015;153(6):981-9.
40. Frankenthaler RA, Byers RM, Luna MA, Callender DL, Wolf P, Goepfert H. Predicting occult lymph node metastasis in parotid cancer. *Archives of Otolaryngology - Head and Neck Surgery*. 1993;119(5):517-20.
41. Huang TT, Chou YF, Wen YH, Chen PR. Resected tumours of the sublingual gland: 15 years' experience. *British Journal of Oral and Maxillofacial Surgery*. 2016;54(6):625-8.
42. Lee SY, Kim BH, Choi EC. Nineteen-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. *Head and Neck*. 2014;36(12):1796-801.
43. Qian K, Guo K, Zheng X, Sun W, Sun T, Chen L, et al. The limited role of elective neck dissection in patients with cN0 salivary gland carcinoma. *Journal of Cranio-Maxillofacial Surgery*. 2019;47(1):47-52.
44. Shang J, Wu Y, Wang W, Wang K, Ge M. Analysis of prognostic risk factors and treatment of parotid cancer. *Oncol Lett*. 2012;3(6):1307-10.
45. Stodulski D, Mikaszewski B, Majewska H, Wisniewski P, Stankiewicz C. Probability and pattern of occult cervical lymph node metastases in primary parotid carcinoma. *European Archives of Oto-Rhino-Laryngology*. 2017;274(3):1659-64.
46. Wang YL, Li DS, Gan HL, Lu ZW, Li H, Zhu GP, et al. Predictive index for lymph node management of major salivary gland cancer. *Laryngoscope*. 2012;122(7):1497-506.
47. Xiao R, Sethi RKV, Feng AL, Fontanarosa JB, Deschler DG. The Role of Elective Neck Dissection in Patients With Adenoid Cystic Carcinoma of the Head and Neck. *Laryngoscope*. 2019.
48. Chen AM, Garcia J, Lee NY, Bucci MK, Eisele DW. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? *International journal of radiation oncology, biology, physics*. 2007;67(4):988-94.
49. Suarez C, Barnes L, Silver CE, Rodrigo JP, Shah JP, Triantafyllou A, et al. Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review. *Auris, nasus, larynx*. 2016;43(5):477-84.
50. Hellquist H, Skalova A, Barnes L, Cardesa A, Thompson LD, Triantafyllou A, et al. Cervical Lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: A Collective International Review. *Advances in therapy*. 2016;33(3):357-68.
51. Bhayani MK, Yener M, El-Naggar A, Garden A, Hanna EY, Weber RS, et al. Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major salivary glands. *Cancer*. 2012;118(11):2872-8.
52. Robbins KT. Indications for selective neck dissection: when, how, and why. *Oncology (Williston Park, NY)*. 2000;14(10):1455-64; discussion 67-9.
53. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. *Archives of otolaryngology--head & neck surgery*. 1994;120(7):699-702.
54. Ferlito A, Silver CE, Rinaldo A. Elective management of the neck in oral cavity squamous carcinoma: current concepts supported by prospective studies. *The British journal of oral & maxillofacial surgery*. 2009;47(1):5-9.
55. de Bree R, Takes RP, Shah JP, Hamoir M, Kowalski LP, Robbins KT, et al. Elective neck dissection in oral squamous cell carcinoma: Past, present and future. *Oral oncology*. 2019;90:87-93.


56. Christensen RK, Bjorndal K, Godballe C, Kroghdal A. Value of fine-needle aspiration biopsy of salivary gland lesions. *Head & neck*. 2010;32(1):104-8.
57. Garrett SL, Trott K, Sebastiano C, Wolf MJ, Rao NK, Curry JM, et al. Sensitivity of Fine-Needle Aspiration and Imaging Modalities in the Diagnosis of Low-Grade Mucoepidermoid Carcinoma of the Parotid Gland. *The Annals of otology, rhinology, and laryngology*. 2019;128(8):755-9.
58. Medina J, Zbaren P, Bradley PJ. Management of Regional Metastases of Malignant Salivary Gland Neoplasms. *Advances in oto-rhino-laryngology*. 2016;78:132-40.
59. Lee SY, Shin HA, Rho KJ, Chung HJ, Kim SH, Choi EC. Characteristics, management of the neck, and oncological outcomes of malignant minor salivary gland tumours in the oral and sinonasal regions. *The British journal of oral & maxillofacial surgery*. 2013;51(7):e142-7.
60. Yu T, Gao QH, Wang XY, Wen YM, Li LJ. Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. *Oncology*. 2007;72(1-2):39-44.
61. Lombardi D, Accorona R, Lambert A, Mercante G, Coropciuc R, Paderno A, et al. Long-term outcomes and prognosis in submandibular gland malignant tumors: A multicenter study. *The Laryngoscope*. 2018;128(12):2745-50.
62. Rajappa SK, Bhakuni YS, Ram D, Shukla H, Ranjan R, Dewan A, et al. A gland of diverse pathology and unpredictable behaviour: our experience of primary submandibular gland malignancies. *International journal of oral and maxillofacial surgery*. 2018;47(10):1243-9.
63. Roh JL, Choi SH, Lee SW, Cho KJ, Nam SY, Kim SY. Carcinomas arising in the submandibular gland: high propensity for systemic failure. *Journal of surgical oncology*. 2008;97(6):533-7.
64. Lim CM, Gilbert M, Johnson JT, Kim S. Is level v neck dissection necessary in primary parotid cancer? *Laryngoscope*. 2015;125(1):118-21.
65. Vander Poorten V, Bradley PJ, Takes RP, Rinaldo A, Woolgar JA, Ferlito A. Diagnosis and management of parotid carcinoma with a special focus on recent advances in molecular biology. *Head & neck*. 2012;34(3):429-40.
66. Lombardi D, McGurk M, Vander Poorten V, Guzzo M, Accorona R, Rampinelli V, et al. Surgical treatment of salivary malignant tumors. *Oral oncology*. 2017;65:102-13.




HED_26667_Figure1_flowchart.tif



A: All primary tumour subsites $n = 36$




B: Patients with parotid gland carcinoma $n = 25$



C: Patients with submandibular gland carcinoma $n = 7$

HED_26667_Figure2_levels.tif



HED_26667_Figure3.tiff

Table 1. Patient and tumour characteristics related to surgical treatment of the neck.

Abbreviations: TND = Therapeutic neck dissection; END = Elective neck dissection; NoND = No neck dissection

Variable	TND (n = 81)	END (n = 259)	NoND (n = 324)
	Number of patients (%)	Number of patients (%)	Number of patients (%)
Sex			
Male	53 (65)	115 (44)	136 (42)
Female	28 (35)	144 (56)	188 (58)
Ratio (male:female)	1.9	0.8	0.7
Age			
≤60	33 (37)	116 (45)	133 (41)
>60	51 (63)	143 (55)	191 (59)
Median	63	61	63
Range	21-88	6-94	11-93
T-classification			
T1/T2	45 (56)	196 (76)	243 (75)
T3/T4	36 (44)	63 (24)	81 (25)
N-classification			
pN0	31 (38)	223 (86)	
pN+	50 (62)	36 (14)	
Metastatic rate	50/81=62%	36/259=14%	
Site			
Parotid gland	48 (59)	163 (63)	122 (37)
Submandibular gland	16 (20)	46 (18)	25 (8)
Sublingual gland	2 (2)	8 (3)	3 (1)
Minor salivary glands	15 (19)	41 (16)	174 (54)
Facial nerve impairment			
Yes	10 (12)	24 (9)	8 (2)
No	71 (88)	235 (91)	316 (98)
Histological grade			
Low-grade	40 (49)	185 (71)	277 (85)
High-grade	41 (51)	74 (29)	47 (15)
Histological subtypes			
Adenoid cystic carcinoma	11 (13.6)	66 (25.5)	75 (23.2)
Mucoepidermoid carcinoma	10 (12.4)	45 (17.4)	60 (18.5)
Polymorphous adenocarcinoma	3 (3.7)	7 (2.7)	57 (17.6)
Acinic cell carcinoma	6 (7.4)	33 (12.7)	22 (6.8)
Carcinoma ex pleomorphic adenoma	11 (13.6)	24 (9.3)	21 (6.5)
Salivary duct carcinoma	17 (21.0)	23 (8.9)	4 (1.2)
Epithelial-myoepithelial carcinoma	2 (2.5)	11 (4.3)	16 (4.9)
Basal cell adenocarcinoma	1 (1.2)	10 (3.9)	15 (4.6)
Squamous cell carcinoma	4 (4.9)	9 (3.5)	8 (2.5)
Adenocarcinoma	8 (9.9)	5 (1.9)	15 (4.6)
Clear cell adenocarcinoma	1 (1.2)	5 (1.9)	6 (1.9)
Secretory carcinoma	1 (1.2)	4 (1.5)	7 (2.2)
Poorly differentiated carcinoma	3 (3.7)	5 (1.9)	3 (0.9)
Myoepithelial carcinoma	0	3 (1.2)	6 (1.9)
Other subtypes	3 (3.7)	9 (3.5)	5 (1.6)
Surgical margins			
Involved	43 (53)	95 (37)	132 (41)
Close/free	38 (47)	164 (63)	192 (59)
Radiotherapy			
None	15 (19)	98 (38)	177 (55)
T-site	15 (19)	98 (38)	76 (23)
T- and N-site	51 (62)	63 (24)	71 (22)

Table 2. Regression analysis of factors associated with cervical lymph node metastases.

Abbreviations: OR = Odds Ratio

Variables	pN+	pN0	Univariate regression		Multivariate regression	
	<i>n</i> = 86 (%)	<i>n</i> = 254 (%)	OR	<i>p</i> -value	OR	<i>p</i> -value
Sex						
Female	29 (33)	111 (44)				
Male	57 (66)	143 (56)	2.5	<0.0001	2.4	0.016
Ratio (male:female)	2.0	0.8				
Age						
≤60	29 (34)	117 (46)				
>60	57 (66)	137 (54)	1.7	0.047	ns	
Median	64	61				
Range	24-88	6-94				
T-classification						
T1/T2	47 (55)	194 (76)				
T3/T4	39 (45)	60 (23)	2.7	<0.001	ns	
Tumour size						
<4 cm	60 (70)	210 (83)				
>4 cm	26 (30)	44 (17)	2.1	0.011	ns	
Site						
Minor gland	8 (9)	49 (19)				
Major gland	78 (91)	205 (81)	2.3	0.036	ns	
Parotid gland	57	154				
Submandibular gland	17	45				
Sublingual gland	4	6				
Facial nerve impairment						
No	69 (80)	237 (93)				
Yes	17 (20)	17 (7)	3.4	0.001	ns	
Histological subtype						
Low-grade	35 (41)	190 (75)				
High-grade	51 (59)	64 (25)	4.3	<0.001	3.0	<0.001
Surgical margins						
Close/free	40 (47)	162 (64)				
Involved	46 (53)	92 (36)	2.0	0.005	ns	
Perineural invasion						
No (218)	14 (16)	90 (35)				
Yes (216)	46 (53)	82 (32)	3.6	<0.001	ns	
Unknown (230)	26 (30)	82 (32)				
Vascular invasion						
No (193)	17 (20)	87 (34)				
Yes (55)	22 (26)	11 (4)	10.2	<0.001	7.0	<0.001
Unknown (416)	47 (55)	156 (61)				

Table 3. Patient and tumour characteristics in patients with occult metastases ($n = 33$)

Abbreviations: ns = not significant; END = elective neck dissection; cN0pN+ = occult metastases

Variable	cN0pN+		Proportion of cN0pN+ in the total group of END patients ($n = 259$)	Univariate analyses	Multivariate analyses
	No of patients	%			
Sex					
Female	15	42	10% (15 of 144)	ns	ns
Male	21	58	18% (21 of 115)		
Ratio (male:female) 1.4					
Age					
≤60	15	42		ns	ns
>60	21	58			
Primary tumour					
Parotid gland	25	69	15% (25 of 163)		
Submandibular gland	7	19	15% (7 of 46)		
Sublingual gland	2	6	25% (2 of 8)		
Minor glands (palate)	2	6	5% (2 of 41)		
T-classification				OR 2.3, $p=0.031$	ns
T1/T2	22	61	11% (22 of 196)		
T3/T4	14	39	22% (14 of 63)		
Tumoursize					
Median 3.0 cm					
Range 1.2-5.5 cm					
Histological subtype					
Adenoid cystic carcinoma	11	31			
<i>Tubulocribiform, $n=7$ (64%)</i>					
<i>Solid, $n=4$ (36%)</i>					
Salivary duct carcinoma	8	22			
Acinic cell carcinoma	4	11			
Mucoepidermoide carcinoma	3	8			
<i>Low-grade, $n=1$ (33%)</i>					
<i>High-grade, $n=2$ (67%)</i>					
Lymphoepithelial carcinoma	3	8			
Adenocarcinoma (low-grade)	1	3			
Squamous cell carcinoma	1	3			
Carcinoma ex pleomorphic adenoma	2	6			
Poorly differentiated carcinoma	2	6			
<i>small cell neuroendocrine, $n=2$ (100%)</i>					
Clear cell carcinoma	1	3			
Histological subtype					
Low-grade	16	44	9% (16 of 185)	OR 3.9, $p<0.001$	OR 3.5, $p=0.01$
High-grade	20	56	27% (20 of 74)		
Facial nerve impairment					
No	27	75		OR 4.6, $p=0.001$	ns
Yes	9	25			
Surgical margins					
Close/free	20	56		ns	ns
Involved	16	44			
Perineural invasion					
No	4	11		OR 5.4, $p=0.003$	ns
Yes	20	56			
Unknown ($n = 12$, 33%)					
Vascular invasion					
No	6	17		OR 14.6, $p<0.001$	OR 15.5, $p<0.001$
Yes	9	25			
Unknown ($n = 21$, 58%)					

Table 4, Description of patients with recurrence in N-site in the group with cN0 and noND. Abbreviations: RT = radiotherapy; NO = no radiotherapy; pTNM = pathological tumour/node/metastasis classification

Tumour site	pTNM	Histological Subtype	Surgical margins	RT	Recurrence	Time to recurrence	Status at last follow-up
Minor gland (palate)	T4aN0M0	Carcinoma ex pleomorphic adenoma	Involved	T-site	N-site	1.1 year	Dead of disease
Parotid gland	T3N0M0	Carcinoma ex pleomorphic adenoma	Involved	T-site	N-site	7 months	Dead of disease
Submandibular gland	T2N0M0	Adenoid cystic carcinoma	Close	NO	N-site	1.5 year	Alive, treated for recurrence
Submandibular gland	T3N0M0	Carcinoma ex pleomorphic adenoma	Close	NO	N-site and T-site	4.1 years	Dead of disease
Minor gland (tongue)	T1N0M0	Polymorphous adenocarcinoma	Free	NO	N-site and T-site	7.9 years	Alive, treated for recurrence
Minor gland (sinus)	T4bN0M0	Epithelial-myoepithelial carcinoma	Involved	NO	N-site and T-site	6 months	Dead of disease
Parotid gland	T1N0M0	Oncocytic carcinoma	Involved	T- and N-site (50 Gy to levels II-III)	N-site and M-site	2.1 years	Alive, treated for recurrence
Parotid gland	T4bN1M0 (intraparotid metastasis)	Squamous cell carcinoma	Involved	T- and N-site (50 Gy to levels II, III and V)	N-site	2.4 years 3 months	Alive, treated for recurrence